Conclusion. Ceftobiprole is a novel, broad-spectrum, parenteral cephalosporin undergoing Phase III clinical trials. Its broad spectrum of activity makes it a candidate for monotherapy of cSSSIs ...

Ceftaroline is a novel, bactericidal injectable broad spectrum cephalosporin being developed as a therapeutic agent for the treatment of gram-positive pathogens including methicillin resistant ...

Extremely broad-spectrum antibiotics, such as the broad-spectrum cephalosporins and the carbapenems, antibiotics of last resort, are already proving totally ineffective against certain strains of ...

Credit: Getty Images. Ceftobiprole is a broad spectrum cephalosporin antibiotic. The Food and Drug Administration (FDA) has accepted the New Drug Application for ceftobiprole, an investigational ...

Experts say ESBL bacteria are gaining anti-resistance strength worldwide, namely against the broad-spectrum antimicrobial agents, cephalosporins that are used to treat humans for life-threatening ...

Certain broadband antibiotics, such as macrolides, fluoroquinolones and cephalosporins, are crucial for human medicine. Few substitute therapies exist for these drugs, which are consequently ...

use of other broad‑spectrum antibiotics has increased. Ashiru-Oredope et al. (2012) found that, in secondary care between 2004 and 2009, there was a decrease in the use of quinolones and second‑ and ...

Ceftobiprole has the potential to be used as monotherapy for the treatment of pneumonia and cSSSIs. Patients with DFIs and osteomyelitis were excluded from the cSSSI clinical trials, and ...

A rapid diagnostic test for multi-resistance to broad-spectrum antibiotics has ... and of carbapenemases (which hydrolyse wide-spectrum cephalosporins and carbapenems in Enterobacteriaceae and ...

Use of broad‑spectrum antibiotics is associated with an increased ... These guidelines should avoid recommending clindamycin and second‑ and third‑generation cephalosporins (especially in older people ...